187 related articles for article (PubMed ID: 32710448)
21. Association between serum erythropoietin levels and renal reversibility in patients with renal impairment from multiple myeloma.
Kobayashi H; Terao T; Tsushima T; Abe Y; Miura D; Narita K; Kitadate A; Takeuchi M; Matsue K
Cancer Med; 2020 Jun; 9(12):4460-4466. PubMed ID: 32311841
[TBL] [Abstract][Full Text] [Related]
22. [Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy].
Xu Y; An G; Deng SH; Sui WW; Feng XY; Li F; Hao M; Wang YF; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):304-8. PubMed ID: 23668201
[TBL] [Abstract][Full Text] [Related]
23. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.
Yadav P; Cockwell P; Cook M; Pinney J; Giles H; Aung YS; Cairns D; Owen RG; Davies FE; Jackson GH; Child JA; Morgan GJ; Drayson MT
BMC Nephrol; 2018 Jul; 19(1):178. PubMed ID: 30012107
[TBL] [Abstract][Full Text] [Related]
24. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M
Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956
[TBL] [Abstract][Full Text] [Related]
25. Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant.
Waszczuk-Gajda A; Małyszko J; Vesole DH; Feliksbrot-Bratosiewicz M; Skwierawska K; Krzanowska K; Kobylińska K; Biecek P; Snarski E; Rodziewicz-Lurzyńska A; Kozłowski P; Stefaniak A; Drozd-Sokołowska J; Ziarkiewicz M; Vyas P; Boguradzki P; Mądry K; Biliński J; Tomaszewska A; Maciejewska M; Urbanowska E; Blajer B; Król M; Król M; Zborowska H; Jurczyszyn A; Dwilewicz-Trojaczek J; Jedrzejczak WW; Basak GW
Transplant Proc; 2020 Sep; 52(7):2186-2192. PubMed ID: 32222395
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment.
Klein U; Neben K; Hielscher T; Heiss C; Ho AD; Goldschmidt H
Ann Hematol; 2011 Apr; 90(4):429-39. PubMed ID: 20857112
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
[TBL] [Abstract][Full Text] [Related]
28. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
29. Response and Dynamics of Renal Function in Transplantation-Eligible Multiple Myeloma Patients Treated with a Novel Agent: The CAREMM-2201 Study.
Kim Y; Park SS; Jeon YW; Yahng SA; Shin SH; Min CK;
Transplant Cell Ther; 2023 Jan; 29(1):55.e1-55.e9. PubMed ID: 36202336
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of
Ahn SY; Park HK; Moon JH; Baek DW; Cho HJ; Sohn SK; Kang SR; Min JJ; Bom HS; Hong CM; Jeong SY; Song GY; Yang DH; Ahn JS; Kim HJ; Jung SH; Lee JJ
Int J Hematol; 2021 May; 113(5):668-674. PubMed ID: 33475961
[TBL] [Abstract][Full Text] [Related]
31. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
[TBL] [Abstract][Full Text] [Related]
32. Current treatments for renal failure due to multiple myeloma.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Pharmacother; 2013 Aug; 14(11):1477-95. PubMed ID: 23705905
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
San-Miguel JF; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Neuwirth R; Boral AL; Esseltine DL; Anderson KC
Leukemia; 2008 Apr; 22(4):842-9. PubMed ID: 18200040
[TBL] [Abstract][Full Text] [Related]
34. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
Khan R; Apewokin S; Grazziutti M; Yaccoby S; Epstein J; van Rhee F; Rosenthal A; Waheed S; Usmani S; Atrash S; Kumar S; Hoering A; Crowley J; Shaughnessy JD; Barlogie B
Leukemia; 2015 May; 29(5):1195-201. PubMed ID: 25640885
[TBL] [Abstract][Full Text] [Related]
35. [Effect of Serum Free Light Chain on Renal Function and Prognosis in Patients with Newly Diagnosed Multiple Myeloma].
Chen XD; Luo XF; Zu YP; Ye H; Li LL; Chen QL; Xie WZ; Yang T; Hu JD; Wei LX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1862-1868. PubMed ID: 31839051
[TBL] [Abstract][Full Text] [Related]
36. Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment.
Song MK; Chung JS; Shin HJ; Moon JH; Lee JJ; Yoon SS; Kim JS; Lee JO; Do YR; Lee HS; Park EK;
Ann Hematol; 2012 Jun; 91(6):889-96. PubMed ID: 22237937
[TBL] [Abstract][Full Text] [Related]
37. Outcome of patients with multiple myeloma and renal failure on novel regimens.
Soleymanian T; Soleimani A; Musavi A; Mojtahedi K; Hamid G
Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):335-40. PubMed ID: 26997388
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
[TBL] [Abstract][Full Text] [Related]
39. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of renal failure recovery in patients with newly diagnosed multiple mieloma.
Peña C; Valladares X; Gajardo C; Russo M; Morales Á; Correa G; Valjalo R
Rev Med Chil; 2019 Nov; 147(11):1374-1381. PubMed ID: 32186597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
